ArticleBMJ open2016
Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends.
Article in BMJ open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Global, regional, and national burden of multiple myeloma from 1990 to 2021 and projections for 2040: a systematic analysis for the global burden of disease 2021 study.Frontiers in epidemiology · 2025Article
- Recent trends in incidence, survival and treatment of multiple myeloma in Finland - a nationwide cohort study.Annals of hematology · 2024Article
- Hematologic malignancies of primary bone marrow involvement: a decade's experience in Bahrain.Hematology, transfusion and cell therapy · 2023Article
- Use of Linked Nordic Registries for Population Studies in Hematologic Cancers: The Case of Multiple Myeloma.Clinical epidemiology · 2023Article
- Update on cancer incidence trends in Canada, 1984 to 2017.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2022Article
- Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients.Journal of clinical medicine · 2022Article
- Article
- Downregulation of microRNA‑25‑3p inhibits the proliferation and promotes the apoptosis of multiple myeloma cells via targeting the PTEN/PI3K/AKT signaling pathway.International journal of molecular medicine · 2021Article
- Long Noncoding RNA H19 Promotes Tumorigenesis of Multiple Myeloma by Activating BRD4 Signaling by Targeting MicroRNA 152-3p.Molecular and cellular biology · 2020Article
- Incidence and mortality of multiple myeloma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016.Journal of hematology & oncology · 2019Article
- At-a-glance - Cancer trends in Canada, 1984 to 2015.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2019Article
- Methods for reducing delays in the diagnosis of multiple myeloma.International journal of hematologic oncology · 2019Article
- Prevalence and Incidence of Multiple Myeloma in Urban Area in China: A National Population-Based Analysis.Frontiers in oncology · 2019Article
- Approach to the Older Adult With Multiple Myeloma.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2019Article
- Epidemiology of multiple myeloma in 17 Latin American countries: an update.Cancer medicine · 2018Article
- Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival.European journal of haematology · 2018Review
- Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry.Haematologica · 2018Article
- Article
- Multiple myeloma presenting in association with gastric phytobezoar.Clinical case reports · 2017Article
- Effects of survivin on FVADT chemotherapy for refractory multiple myeloma.Experimental and therapeutic medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesThe increased incidence of multiple myeloma (MM) across China and East Asia stimulated us to examine the current rates in Great Britain, where rates increased dramatically in the second half of the 20th century. However, rates have been stable and high during this period in Malmö, Sweden, where there is a keen interest in MM. We thus assessed recent changes in MM incidence in Great Britain, Sweden overall, and Malmö, Sweden, and examined how these changes might explain recent reports of increased MM incidence across Asia.
designEstimation of MM incidence for Great Britain, Sweden overall, and Malmö, Sweden. POPULATIONS: MM incidence data for Great Britain (1975-2009) were obtained from Cancer Research UK and for Sweden (1970-2009) from the Swedish Cancer Registry. MM incidence data from Malmö, Sweden, were available from 1950 to 2012.
main outcome measuresAge-specific incidence of MM in Great Britain, Sweden overall, and Malmö, Sweden.
resultsMM incidence in Great Britain, Sweden overall, and Malmö increased progressively with age, even among the oldest group. The MM age-adjusted incidence (European standard population) increased by 69% from 1975-1979 to 2005-2009 in Great Britain, from 3.2/100,000 to 5.4/100,000. The largest increases occurred among those 70-79 years of age, for whom rates increased from 17.9/100,000 to 33.6/100,000; reflecting an increase of 69%. During this same period, the age-adjusted incidence (European stand population) in Sweden overall remained stable, at approximately 4.7/100,000.
conclusionsMM age-specific incidence is now similar in Great Britain, Sweden overall, and Malmö. We believe this is a result of improvements in case ascertainment in Great Britain, particularly among the elderly. Similar changes can be predicted to occur across Asia as improved access to healthcare contributes to better diagnosis of MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.